NCT07028528View on ClinicalTrials.gov

Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Diabetic Peripheral Neuropathy
Interventions
DIETARY_SUPPLEMENT

Levagen+

Participants will take 1 capsule twice daily with water after food. Each capsule will contain: A175mg containing 150 mg of palmitoylethanolamide (PEA). Total daily dose of 350mg Levagen+ containing 300 mg PEA

OTHER

Placebo

Participants will take 1 capsule twice daily with water after food. Each capsule will contain microcrystalline cellulose \[MCC\]

Trial Locations (1)

4006

RECRUITING

RDC Clinical, Fortitude Valley

All Listed Sponsors
collaborator

Gencor Pacific Limited

UNKNOWN

lead

RDC Clinical Pty Ltd

INDUSTRY